{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:10:59Z","timestamp":1778314259429,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jsat.2019.05.004","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T09:30:11Z","timestamp":1557307811000},"page":"7-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Medication-enhanced behavior therapy for alcohol use disorder: Naltrexone, Alcoholics Anonymous Facilitation, and OPRM1 genetic variation"],"prefix":"10.1016","volume":"104","author":[{"given":"Scott H.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly S.","family":"Walitzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Swiatek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Paine Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolfo","family":"Qui\u00f1ones-Lombra\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Shyhalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jsat.2019.05.004_bb0005","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1521-0391.2012.00270.x","article-title":"Do manualized psychosocial interventions help reduce relapse among alcohol-dependent adults treated with naltrexone or placebo? A meta-analysis","volume":"21","author":"Agosti","year":"2012","journal-title":"The American Journal on Addictions"},{"issue":"7","key":"10.1016\/j.jsat.2019.05.004_bb0010","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/j.1530-0277.2003.tb02873.x","article-title":"Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: Rationale and methods","volume":"27","author":"Anton","year":"2003","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"3","key":"10.1016\/j.jsat.2019.05.004_bb0015","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1521-0391.2014.12102.x","article-title":"Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans","volume":"23","author":"Arias","year":"2014","journal-title":"American Journal on Addictions"},{"issue":"8","key":"10.1016\/j.jsat.2019.05.004_bb0020","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.euroneuro.2015.04.013","article-title":"Increased mesolimbic cue-reactivity in carriers of the mu-opioid-receptor gene OPRM1 A118G polymorphism predicts drinking outcome: A functional imaging study in alcohol dependent subjects","volume":"25","author":"Bach","year":"2015","journal-title":"European Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.jsat.2019.05.004_bb0025","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.alcohol.2015.03.003","article-title":"Corticostriatal circuity and habitual ethanol seeking","volume":"49","author":"Barker","year":"2015","journal-title":"Alcohol"},{"key":"10.1016\/j.jsat.2019.05.004_bb0030","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.neuropharm.2017.04.028","article-title":"Influence of stress associated with chronic alcohol exposure on drinking","volume":"122","author":"Becker","year":"2017","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.jsat.2019.05.004_bb0035","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1369-1600.2012.00442.x","article-title":"Association of mu-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: A systematic review and meta-analysis","volume":"17","author":"Chamorro","year":"2012","journal-title":"Addiction Biology"},{"issue":"12","key":"10.1016\/j.jsat.2019.05.004_bb0040","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/FPC.0b013e32834c5445","article-title":"OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence","volume":"21","author":"Coller","year":"2011","journal-title":"Pharmacogenetics and Genomics"},{"issue":"6","key":"10.1016\/j.jsat.2019.05.004_bb0045","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/acer.12067","article-title":"The declining efficacy of naltrexone pharmacotherapy for alcohol use disorders over time: A multivariate meta-analysis","volume":"37","author":"Del Re","year":"2013","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"6","key":"10.1016\/j.jsat.2019.05.004_bb0050","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/add.12875","article-title":"The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: A meta-analysis","volume":"110","author":"Donoghue","year":"2015","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.jsat.2019.05.004_bb0055","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/FPC.0000000000000128","article-title":"OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients","volume":"25","author":"Foulds","year":"2015","journal-title":"Pharmacogenetics and Genomics"},{"issue":"10","key":"10.1016\/j.jsat.2019.05.004_bb0060","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1111\/acer.12513","article-title":"Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking","volume":"38","author":"Fridberg","year":"2014","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/j.jsat.2019.05.004_bb0065","doi-asserted-by":"crossref","unstructured":"Fucito, L.M., Park, A., Gulliver, S.B., Mattson, M.E., Gueorguieva, R.V., O'Malley, S.S. (2012). Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence. Biological Psychiatry 72(10), 832\u2013838. doi.org\/https:\/\/doi.org\/10.1016\/j.biopsych.2012.03.023.","DOI":"10.1016\/j.biopsych.2012.03.023"},{"issue":"4","key":"10.1016\/j.jsat.2019.05.004_bb0070","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1530-0277.2007.00339.x","article-title":"Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: Results from the VA cooperative study","volume":"31","author":"Gelernter","year":"2007","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"11","key":"10.1016\/j.jsat.2019.05.004_bb0075","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.biopsych.2006.09.038","article-title":"New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials","volume":"61","author":"Gueorguieva","year":"2007","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jsat.2019.05.004_bb0080","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.pnpbp.2012.09.014","article-title":"Association study of DRD2 and MAOA genes with subtyped alcoholism comorbid with bipolar disorder in Han Chinese","volume":"40","author":"Hu","year":"2013","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"1","key":"10.1016\/j.jsat.2019.05.004_bb0085","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1037\/0022-006X.59.1.12","article-title":"Clinical significance: A statistical approach to defining meaningful change in psychotherapy research","volume":"59","author":"Jacobson","year":"1991","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"13","key":"10.1016\/j.jsat.2019.05.004_bb0090","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2217\/pgs.14.121","article-title":"Genetic polymorphisms and response to medications for alcohol use disorders: A systematic review and meta-analysis","volume":"15","author":"Jonas","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.jsat.2019.05.004_bb0095","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1037\/a0028445","article-title":"The Short Inventory of Problems-revised (SIP-R): Psychometric properties within a large, diverse sample of substance use disorder treatment seekers","volume":"27","author":"Kiluk","year":"2013","journal-title":"Psychology of Addictive Behaviors"},{"issue":"8","key":"10.1016\/j.jsat.2019.05.004_bb0100","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: A neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.jsat.2019.05.004_bb0105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1369-1600.2012.00471.x","article-title":"Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment","volume":"18","author":"Kranzler","year":"2013","journal-title":"Addiction Biology"},{"key":"10.1016\/j.jsat.2019.05.004_bb0110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0149-7189(79)90094-6","article-title":"Assessment of client\/patient satisfaction: Development of a general scale","volume":"2","author":"Larsen","year":"1979","journal-title":"Evaluation and Program Planning"},{"issue":"2","key":"10.1016\/j.jsat.2019.05.004_bb0115","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.gene.2015.01.064","article-title":"Clinically relevant genetic biomarkers from the brain in alcoholism with representation on high resolution chromosome ideograms","volume":"560","author":"Manzardo","year":"2015","journal-title":"Gene"},{"issue":"5","key":"10.1016\/j.jsat.2019.05.004_bb0120","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jsat.2012.12.002","article-title":"Factor analysis and validity of a short six-item version of the Desires for Alcohol Questionnaire","volume":"44","author":"Mo","year":"2013","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.jsat.2019.05.004_bb0125","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1001\/jamapsychiatry.2014.3053","article-title":"Naltrexone vs placebo for the treatment of alcohol dependence a randomized clinical trial","volume":"72","author":"Oslin","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.jsat.2019.05.004_bb0130","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/01.jcp.0000245566.52401.20","article-title":"The status of naltrexone in the treatment of alcohol dependence - Specific effects on heavy drinking","volume":"26","author":"Pettinati","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1016\/j.jsat.2019.05.004_bb0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15288\/jsa.1997.58.7","article-title":"Matching alcoholism treatments to client heterogeneity: Project MATCH post-treatment drinking outcomes","volume":"58","author":"Project MATCH Research Group","year":"1997","journal-title":"Journal of Studies on Alcohol"},{"issue":"6","key":"10.1016\/j.jsat.2019.05.004_bb0140","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/j.1530-0277.1998.tb03912.x","article-title":"Matching alcoholism treatments to client heterogeneity: Project MATCH three-year drinking outcomes","volume":"22","author":"Project MATCH Research Group","year":"1998","journal-title":"Alcoholism: Clinical and Experimental Research"},{"issue":"11","key":"10.1016\/j.jsat.2019.05.004_bb0145","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.3109\/10826084.2010.482427","article-title":"Subjective responses to alcohol consumption as endophenotypes: Advancing behavioral genetics in etiological and treatment models of alcoholism","volume":"45","author":"Ray","year":"2010","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.jsat.2019.05.004_bb0155","doi-asserted-by":"crossref","first-page":"E116","DOI":"10.1111\/j.1530-0277.2012.01916.x","article-title":"Subjective response to alcohol among alcohol-dependent individuals: Effects of the mu-opioid receptor (OPRM1) gene and alcoholism severity","volume":"37","author":"Ray","year":"2013","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"3","key":"10.1016\/j.jsat.2019.05.004_bb0160","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/alcalc\/agt183","article-title":"Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol","volume":"49","author":"Ray","year":"2014","journal-title":"Alcohol and Alcoholism"},{"key":"10.1016\/j.jsat.2019.05.004_bb0165","article-title":"Opioid antagonists for alcohol dependence","volume":"12","author":"Rosner","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"13","key":"10.1016\/j.jsat.2019.05.004_bb0175","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1038\/npp.2017.74","article-title":"Predictors of naltrexone response in a randomized trial: Reward-related brain activation, OPRM1 genotype, and smoking status","volume":"42","author":"Schacht","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.jsat.2019.05.004_bb0180","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2217\/pgs.12.99","article-title":"Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone","volume":"13","author":"Setiawan","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"6","key":"10.1016\/j.jsat.2019.05.004_bb0185","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.15288\/jsad.2011.72.1012","article-title":"Adherence monitoring in naltrexone pharmacotherapy trials: A systematic review","volume":"72","author":"Swift","year":"2011","journal-title":"Journal of Studies on Alcohol and Drugs"},{"issue":"3","key":"10.1016\/j.jsat.2019.05.004_bb0195","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1360-0443.2008.02467.x","article-title":"Facilitating involvement in alcoholics anonymous during out-patient treatment: A randomized clinical trial","volume":"104","author":"Walitzer","year":"2009","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.jsat.2019.05.004_bb0200","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00702-011-0628-3","article-title":"Family-based association analysis of alcohol dependence in the COGA sample and replication in the Australian twin-family study","volume":"118","author":"Wang","year":"2011","journal-title":"Journal of Neural Transmission"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547218304823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547218304823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:49:20Z","timestamp":1760039360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547218304823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":37,"alternative-id":["S0740547218304823"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2019.05.004","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication-enhanced behavior therapy for alcohol use disorder: Naltrexone, Alcoholics Anonymous Facilitation, and OPRM1 genetic variation","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2019.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}